A novel view on an old drug, 5-fluorouracil: an unexpected RNA modifier with intriguing impact on cancer cell fate.


Journal

NAR cancer
ISSN: 2632-8674
Titre abrégé: NAR Cancer
Pays: England
ID NLM: 101769553

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 18 03 2021
revised: 01 07 2021
accepted: 09 08 2021
entrez: 19 8 2021
pubmed: 20 8 2021
medline: 20 8 2021
Statut: epublish

Résumé

5-Fluorouracil (5-FU) is a chemotherapeutic drug widely used to treat patients with solid tumours, such as colorectal and pancreatic cancers. Colorectal cancer (CRC) is the second leading cause of cancer-related death and half of patients experience tumour recurrence. Used for over 60 years, 5-FU was long thought to exert its cytotoxic effects by altering DNA metabolism. However, 5-FU mode of action is more complex than previously anticipated since 5-FU is an extrinsic source of RNA modifications through its ability to be incorporated into most classes of RNA. In particular, a recent report highlighted that, by its integration into the most abundant RNA, namely ribosomal RNA (rRNA), 5-FU creates fluorinated active ribosomes and induces translational reprogramming. Here, we review the historical knowledge of 5-FU mode of action and discuss progress in the field of 5-FU-induced RNA modifications. The case of rRNA, the essential component of ribosome and translational activity, and the plasticity of which was recently associated with cancer, is highlighted. We propose that translational reprogramming, induced by 5-FU integration in ribosomes, contributes to 5-FU-driven cell plasticity and ultimately to relapse.

Identifiants

pubmed: 34409299
doi: 10.1093/narcan/zcab032
pii: zcab032
pmc: PMC8364333
doi:

Types de publication

Journal Article

Langues

eng

Pagination

zcab032

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of NAR Cancer.

Références

Pharmacol Ther. 1990;48(2):189-222
pubmed: 2293239
Nucleic Acids Res. 2011 Oct;39(19):8430-44
pubmed: 21745813
FASEB J. 2015 Aug;29(8):3472-82
pubmed: 25934701
Cancer Res. 1954 Feb;14(2):111-4
pubmed: 13126944
Cancer Res. 2010 Jul 15;70(14):6026-35
pubmed: 20587522
J Pharm Biomed Anal. 2015 Jun 10;110:58-66
pubmed: 25804433
Br J Cancer. 2015 May 26;112(11):1725-32
pubmed: 25965164
J Biol Chem. 2011 Sep 16;286(37):32552-62
pubmed: 21795683
Cancer Discov. 2018 Dec;8(12):1614-1631
pubmed: 30266814
Angew Chem Int Ed Engl. 2015 Jan 7;54(2):451-5
pubmed: 25417815
J Biol Chem. 1994 Jun 10;269(23):16269-75
pubmed: 8206932
Cancer Sci. 2020 Sep;111(9):3142-3154
pubmed: 32536012
Cancer Res. 1986 Jan;46(1):20-8
pubmed: 2415245
Int J Biol Macromol. 2017 Jan;94(Pt A):728-734
pubmed: 27765567
Nat Commun. 2022 Jan 10;13(1):173
pubmed: 35013311
Nucleic Acids Res. 2007;35(2):550-8
pubmed: 17169984
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
Biochemistry. 1998 Jan 6;37(1):344-51
pubmed: 9425056
Nucleic Acids Res. 2019 Dec 16;47(22):11807-11825
pubmed: 31722427
Fundam Clin Pharmacol. 2000 Mar-Apr;14(2):147-54
pubmed: 10796062
Biomed Pharmacother. 2021 May;137:111285
pubmed: 33485118
FEBS Lett. 2014 Aug 19;588(16):2571-9
pubmed: 24747423
Trends Biochem Sci. 2002 Jul;27(7):344-51
pubmed: 12114023
J Pharm Anal. 2021 Feb;11(1):77-87
pubmed: 33717614
Nucleic Acids Res. 2016 Sep 19;44(16):e135
pubmed: 27302133
Pharmacol Ther. 1980;8(3):629-51
pubmed: 6992162
Ann Oncol. 2004 Jul;15(7):1025-32
pubmed: 15205195
Mol Cancer Ther. 2005 May;4(5):855-63
pubmed: 15897250
Biology (Basel). 2020 May 06;9(5):
pubmed: 32384705
Cancer Res. 1982 Aug;42(8):3005-9
pubmed: 6212116
Front Pharmacol. 2018 Jun 06;9:606
pubmed: 29928232
Nucleic Acids Res. 1991 Nov 25;19(22):6139-44
pubmed: 1956773
Mol Pharmacol. 1983 Mar;23(2):540-6
pubmed: 6835205
Nucleic Acids Res. 2010 May;38(9):e104
pubmed: 20123731
Biomolecules. 2018 Jun 05;8(2):
pubmed: 29874862
PLoS Biol. 2009 Apr 28;7(4):e91
pubmed: 19402749
Cancer Res. 1987 Feb 15;47(4):979-82
pubmed: 3802103
Cancer Res. 1986 Aug;46(8):3866-70
pubmed: 2942236
NAR Cancer. 2020 Dec 22;2(4):zcaa036
pubmed: 34316693
J Cell Physiol. 2019 Mar;234(3):2306-2316
pubmed: 30191973
Oncotarget. 2017 Jul 11;8(28):46219-46233
pubmed: 28515355
EMBO J. 2010 Jun 2;29(11):1865-76
pubmed: 20453831
J Biol Chem. 2003 Aug 8;278(32):29509-14
pubmed: 12764137
J Pharm Pharmacol. 2005 May;57(5):573-8
pubmed: 15901346
Yeast. 2007 Oct;24(10):861-70
pubmed: 17640085
J Biol Chem. 2010 Apr 16;285(16):12416-25
pubmed: 20159984
Annu Rev Biochem. 1970;39:183-226
pubmed: 4920820
J Biol Chem. 2007 Mar 16;282(11):8052-9
pubmed: 17242401
Semin Oncol. 2017 Feb;44(1):13-23
pubmed: 28395758
J Biol Chem. 1986 Jan 5;261(1):21-4
pubmed: 3941072
Prz Gastroenterol. 2019;14(2):89-103
pubmed: 31616522
Nucleic Acids Res. 2013 Jan;41(Database issue):D377-86
pubmed: 23193289
Br J Cancer. 1990 Mar;61(3):415-9
pubmed: 2328208
Nat Chem Biol. 2019 Jan;15(1):88-94
pubmed: 30531910
Lancet. 2010 Mar 20;375(9719):1030-47
pubmed: 20304247
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Nat Rev Cancer. 2020 Dec;20(12):743-756
pubmed: 33033407
J Pharmacol Exp Ther. 2002 Jun;301(3):797-802
pubmed: 12023506
Biosci Rep. 2020 May 29;40(5):
pubmed: 32400857
Cancer Res. 1991 Nov 1;51(21):5806-12
pubmed: 1933851
J Cell Physiol. 2011 Jul;226(7):1868-78
pubmed: 21506117
Nature. 2017 Nov 23;551(7681):472-477
pubmed: 29143818
Cancer Res. 2010 Jun 1;70(11):4767-77
pubmed: 20501855
Biochem J. 2015 May 1;467(3):387-98
pubmed: 25628018
J Biol Chem. 1985 Mar 10;260(5):3006-14
pubmed: 3972814
Nucleic Acids Res. 2013 Jan;41(Database issue):D262-7
pubmed: 23118484
Mol Pharmacol. 2016 Jan;89(1):53-62
pubmed: 26494862
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1795-9
pubmed: 9050858
Drug Metab Dispos. 2011 Jan;39(1):132-9
pubmed: 20930123
Cancer Res. 1954 Feb;14(2):119-23
pubmed: 13126946
Clin Genet. 2008 Feb;73(2):103-12
pubmed: 18005359
Nat Rev Cancer. 2020 Jul;20(7):398-411
pubmed: 32488200
Tumour Biol. 2017 Apr;39(4):1010428317697553
pubmed: 28381160
Cancer Cell. 2013 Sep 9;24(3):318-30
pubmed: 24029231
Cancer Res. 2007 Feb 1;67(3):940-5
pubmed: 17283124
Arch Med Sci. 2020 May 04;16(4):820-824
pubmed: 32542083
Nat Rev Cancer. 2003 May;3(5):330-8
pubmed: 12724731
Cancer Res. 1979 Jul;39(7 Pt 1):2406-13
pubmed: 156065
Cell. 2018 Aug 9;174(4):843-855.e19
pubmed: 30017245
Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):12934-12939
pubmed: 29158377
Br J Cancer. 2003 Aug 18;89(4):754-62
pubmed: 12915890
BMC Genomics. 2006 Apr 03;7:68
pubmed: 16584549
Saudi Dent J. 2019 Oct;31(4):395-416
pubmed: 31700218
J Biol Chem. 1981 Oct 10;256(19):9802-5
pubmed: 7275977
Bull World Health Organ. 2016 Oct 01;94(10):735-742
pubmed: 27843163
Oncologist. 2014 Nov;19(11):1156-68
pubmed: 25326159
PLoS One. 2009 Sep 25;4(9):e7147
pubmed: 19779612
Nucleic Acids Res. 2016 Sep 19;44(16):7884-95
pubmed: 27257078
Gastroenterology. 2007 Dec;133(6):1858-68
pubmed: 18054558
Biosci Rep. 2019 Dec 20;39(12):
pubmed: 31742586
Cancer Res. 1987 Apr 15;47(8):2203-6
pubmed: 3829006
Cancer Res. 1984 May;44(5):1847-51
pubmed: 6713387
Cancer Res. 1978 May;38(5):1250-7
pubmed: 639058
J Biol Chem. 1973 Jan 10;248(1):63-8
pubmed: 4348213
Nat Commun. 2020 Oct 21;11(1):5321
pubmed: 33087710
PLoS One. 2013 Nov 01;8(11):e78172
pubmed: 24223771
Biomolecules. 2018 Oct 03;8(4):
pubmed: 30282949
Nucleosides Nucleotides Nucleic Acids. 2017 Jan 2;36(1):7-30
pubmed: 27759477
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Trends Biochem Sci. 2015 Oct;40(10):560-575
pubmed: 26410597
Nucleic Acids Res. 2013 Sep;41(17):8308-18
pubmed: 23821664
Adv Biol Regul. 2018 May;68:77-87
pubmed: 29221990
Proc Natl Acad Sci U S A. 1987 Aug;84(15):5439-43
pubmed: 3110788
J Biol Chem. 1988 Mar 25;263(9):4467-73
pubmed: 3346255
Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:663-687
pubmed: 29309257
Pharmacol Ther. 1990;48(3):381-95
pubmed: 1707544
Presse Med. 2019 Mar;48(3 Pt 2):e159-e174
pubmed: 30879894
J Chromatogr A. 2001 May 4;916(1-2):215-24
pubmed: 11382294
Pflugers Arch. 2004 Feb;447(5):728-34
pubmed: 12856181
Pharmacol Res. 2007 Sep;56(3):248-53
pubmed: 17702597
Nature. 1957 Mar 30;179(4561):663-6
pubmed: 13418758
Cancer Res. 1975 Nov;35(11 Pt 1):3014-20
pubmed: 171060
Biochimie. 2012 Jul;94(7):1521-32
pubmed: 22342225
Cell Mol Life Sci. 2009 Mar;66(5):788-99
pubmed: 18979208
Cell Oncol (Dordr). 2019 Dec;42(6):757-768
pubmed: 31359293
Oncol Rep. 2010 Jan;23(1):121-8
pubmed: 19956872
Clin Pharmacokinet. 1989 Apr;16(4):215-37
pubmed: 2656050
Science. 2006 May 12;312(5775):902-6
pubmed: 16690864
World J Gastroenterol. 2014 Nov 14;20(42):15682-90
pubmed: 25400452
Mol Aspects Med. 2013 Apr-Jun;34(2-3):529-47
pubmed: 23506887
Cancer Res. 1986 Apr;46(4 Pt 1):1754-8
pubmed: 3456267

Auteurs

Mounira Chalabi-Dchar (M)

Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France.

Tanguy Fenouil (T)

Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France.

Christelle Machon (C)

Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France.

Anne Vincent (A)

Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France.

Frédéric Catez (F)

Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France.

Virginie Marcel (V)

Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France.

Hichem C Mertani (HC)

Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France.

Jean-Christophe Saurin (JC)

Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France.

Philippe Bouvet (P)

Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France.

Jérôme Guitton (J)

Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France.

Nicole Dalla Venezia (ND)

Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France.

Jean-Jacques Diaz (JJ)

Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France.

Classifications MeSH